Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases

BACKGROUND: MAP kinase inhibitor (MAPKi) therapy for BRAF mutated melanoma is characterized by high response rates but development of drug resistance within a median progression-free survival (PFS) of 9–12 months. Understanding mechanisms of resistance and identifying effective therapeutic alternati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zila, Nina, Bileck, Andrea, Muqaku, Besnik, Janker, Lukas, Eichhoff, Ossia M., Cheng, Phil F., Dummer, Reinhard, Levesque, Mitchell P., Gerner, Christopher, Paulitschke, Verena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844114/
https://www.ncbi.nlm.nih.gov/pubmed/29541007
http://dx.doi.org/10.1186/s12014-018-9189-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844114/
https://www.ncbi.nlm.nih.gov/pubmed/29541007
http://dx.doi.org/10.1186/s12014-018-9189-x

Ejemplares similares